Markers released top-line results today after previously reporting the trial succeeded.
Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%
In short
Moderna and Merck's mRNA cancer vaccine demonstrated a 42% reduction in death and recurrence rates, indicating promising outcomes for patients and a positive impact on their care.
Key points
- The vaccine's effectiveness is significant, reducing death and recurrence by 42%.: The vaccine's effectiveness is significant, reducing death and recurrence by 42%.
- The study results suggest a positive impact on patient care.: The study results suggest a positive impact on patient care.
- The findings are promising for patients and could lead to better outcomes.: The findings are promising for patients and could lead to better outcomes.